Literature DB >> 24298352

Long-term Angiogenesis Efficacy Using a Heparin-Conjugated Fibrin (HCF) Delivery System with HBM-MSCs.

Ae-Kyeong Kim1, Min-Hee Kim, Byung-Soo Kim, Dong-Ik Kim.   

Abstract

BACKGROUND AND OBJECTIVES: Heparin-conjugated fibrin (HCF) is suitable for the release and localization of bFGF. We analyzed the effects of a bFGF delivery system using HCF with human bone marrow-derived mesenchymal stem cells (HBM- MSCs) in a dog ischemic limb model. METHODS AND
RESULTS: Animals were divided into HBM-MSCs, HBM-MSCs+HCF, bFGF-HCF, and HBM-MSCs+ bFGF-HCF groups. A total of 1×10(7) HBM-MSCs were injected per animal, and the amount of bFGF was 1 mg per dog. Ischemic muscles were harvested at eight weeks and six months after injection of cells. The HBM-MSCs+ bFGF-HCF group exhibited decreased proportions of capillaries and arterioles six months after transplantation. However, there were more cells positive for the angiogenic factors, VEGF and PDGF, in the eight-week specimens compared with those harvested six months after transplantation.
CONCLUSIONS: Our results demonstrated that a single injection of HBM-MSCs did not have significant long-term angiogenic effects; however, a bFGF delivery system using HCF exerted prolonged angiogenic effects when combined with HBM-MSCs.

Entities:  

Keywords:  Angiogenesis; HBM-MSCs; Heparin-conjugated fibrin; Ischemia; Vascular disease

Year:  2012        PMID: 24298352      PMCID: PMC3840984          DOI: 10.15283/ijsc.2012.5.1.23

Source DB:  PubMed          Journal:  Int J Stem Cells        ISSN: 2005-3606            Impact factor:   2.500


  27 in total

1.  Angiogenesis facilitated by autologous whole bone marrow stem cell transplantation for Buerger's disease.

Authors:  Dong-Ik Kim; Mi-Jung Kim; Jin-Hyun Joh; Sung-Wook Shin; Young-Soo Do; Ji-Young Moon; Na-Ri Kim; Joung-Eun Lim; Ae-Kyeong Kim; Hyun-Seon Eo; Byung-Soo Kim; Seung-Woo Cho; Seung-Hye Yang; Chan-Jeoung Park; Jong-Sup Shim
Journal:  Stem Cells       Date:  2006-01-26       Impact factor: 6.277

2.  Derivation, expansion and characterization of clinical grade mesenchymal stem cells from umbilical cord matrix using cord blood serum.

Authors:  Khushnuma Cooper; Anish SenMajumdar; Chandra Viswanathan
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

3.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.

Authors:  T Asahara; H Masuda; T Takahashi; C Kalka; C Pastore; M Silver; M Kearne; M Magner; J M Isner
Journal:  Circ Res       Date:  1999-08-06       Impact factor: 17.367

4.  Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities.

Authors:  Y Tabata; Y Ikada
Journal:  Biomaterials       Date:  1999-11       Impact factor: 12.479

5.  Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector.

Authors:  Yao Liang Tang; Yi Tang; Y Clare Zhang; Keping Qian; Leping Shen; M Ian Phillips
Journal:  J Am Coll Cardiol       Date:  2005-10-04       Impact factor: 24.094

6.  Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets.

Authors:  M Aoki; R Morishita; Y Taniyama; I Kida; A Moriguchi; K Matsumoto; T Nakamura; Y Kaneda; J Higaki; T Ogihara
Journal:  Gene Ther       Date:  2000-03       Impact factor: 5.250

7.  Development of fibrin derivatives for controlled release of heparin-binding growth factors.

Authors:  S E Sakiyama-Elbert; J A Hubbell
Journal:  J Control Release       Date:  2000-04-03       Impact factor: 9.776

8.  Delivery of basic fibroblast growth factor using heparin-conjugated fibrin for therapeutic angiogenesis.

Authors:  Hee Seok Yang; Suk Ho Bhang; Jin Wook Hwang; Dong-Ik Kim; Byung-Soo Kim
Journal:  Tissue Eng Part A       Date:  2010-06       Impact factor: 3.845

9.  Hyaluronate-heparin conjugate gels for the delivery of basic fibroblast growth factor (FGF-2).

Authors:  Lin-Shu Liu; Chee-Keng Ng; Andrea Y Thompson; James W Poser; Robert C Spiro
Journal:  J Biomed Mater Res       Date:  2002-10

10.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

Authors:  A Yayon; M Klagsbrun; J D Esko; P Leder; D M Ornitz
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

View more
  1 in total

Review 1.  ETV2/ER71 Transcription Factor as a Therapeutic Vehicle for Cardiovascular Disease.

Authors:  Dong Hun Lee; Tae Min Kim; Joo Kyung Kim; Changwon Park
Journal:  Theranostics       Date:  2019-08-09       Impact factor: 11.556

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.